Dr. Lal Pathlabs Limited

==> picture [24 x 49] intentionally omitted <==

==> picture [253 x 29] intentionally omitted <==

November 6, 2020

National Stock Exchange of India Bombay Stock Exchange Limited Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Sandra Kurla Complex Sandra (E) Dalal Street Mumbai - 400 051. Mumbai- 400001

Subject: Press Release for Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2020

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2020.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited

==> picture [75 x 35] intentionally omitted <==

Rajat Kalra Company Secretary and Legal Head Encl: As above

Rcgd. Offi,e: Dr. Lal fot'tlcbs LI" .• s, __ t E, Se.:tor-18. r,• ,," , New De!'1i • l l :)55, +91-l l-3c: 2.[- ] •. Fi')(' +91-l J-2; ;:;:,213 .. Corporate Offi,e: Dr. Lal 1'<1U1Lat! L!? !2th f:, -� T.: .. tr fl, SAS Tc,,.er. M�J',•ty. Se.::or-38, Gur�gram- 122 OC.>J. H;;:,Jr,, +9l-1Z4-3C ::;-s:o. Fax: +91-124-4234-•.:.S E-m.>il: falpt"laf :.:·[1] •fi3:hlab5 ., • .,. Web: ',',W 'lalrathla::,, CV l, CIN No.: l7%17;::)Ll'Y,_jPLC065)�3

==> picture [150 x 35] intentionally omitted <==

For Immediate Release

November 6, 2020

Dr. Lal PathLabs Limited records revenue of Rs 431.9 Cr in Q2 FY 2020-21

New Delhi, India, November 6, 2020 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended September 30, 2020

Consolidated Performance Highlights: Q2 FY 2020-21 vs Q2 FY 2019-20 Revenue: Rs 431.9 Cr, a growth of 18.2% Normalised EBITDA at Rs 134.7 Cr with margin at 31.2% PBT at Rs 116.6 Cr with margin at 27.0%, and PAT Rs 87.1 Cr with margin at 20.2%

Operating Revenue increased by 18.2% in Q2 FY21 to Rs. 431.9 Cr vs Rs 365.6 Cr in Q2 FY20
Covid contributed 17% to Revenue in Q2 FY21 with 3.08 lacs. RTPCR tests
Normalised EBITDA (after adjustment for stock based compensation & CSR cost) for Q2 FY21 is at Rs. 134.7.0 Cr Vs Rs 113.5 Cr in the same quarter last year
PBT is at Rs 116.6 Cr in Q2 FY21 vs Rs 102.3 Cr. in Q2 last year
Profit after Tax in Q2 FY21 at Rs. 87.1 Cr as compared to Rs 81.0 Cr in Q2 last year
Interim Dividend of Rs. 6 per equity share of Rs. 10 each has been approved by the Board

Financial Overview (Consolidated) in Rs Cr

==> picture [425 x 175] intentionally omitted <==

----- Start of picture text ----- Particulars Q2 FY21 Q2 FY20 Gr % FH FY21 FH FY20 Gr %Revenue 431.9 365.6 18.2% 697.9 700.8 -0.4%Expenditure 304.7 256.7 522.4 496.8EBITDA 127.3 108.9 16.9% 175.5 204.0 -14.0%Adj for Stock Based7.4 4.6 13.0 8.5Compensation & CSR costNormalised EBITDA 134.7 113.5 18.7% 188.5 212.5 -11.3%Normalised Margins 31.2% 31.0% 27.0% 30.3%Other income 12.9 14.8 24.3 29.2PBT 116.6 102.3 14.0% 154.7 191.7 -19.3%Margins 27.0% 28.0% 22.2% 27.4%PAT 87.1 81.0 7.5% 115.5 140.1 -17.6%Margins 20.2% 22.2% 16.5% 20.0%EPS (Basic) 10.34 9.77 5.8% 13.79 16.91 -18.4%EPS (Diluted) 10.31 9.75 5.7% 13.75 16.86 -18.4%----- End of picture text -----

Dr. Lal Pathlabs Limited 12[th] Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com

==> picture [150 x 35] intentionally omitted <==

About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its’ integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2020 the company has 216 clinical laboratories (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 3,095 Patient Service Centers (PSCs) and 6,995 Pickup Points (PUPs). Its’ customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Prakash Goel Chief Financial Officer Dr. Lal PathLabs Limited

+91 124 3016500 [email protected]

Mittali Bharti Adfactors PR

+91 9871154558 [email protected]

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

12[th] Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com

AI assistant